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By the beginning of 2021 the world welcomed 
encouraging news on several candidate 
vaccines for COVID-19. Pfizer- BioNTech, 
Moderna, Oxford/AstraZeneca and the 
Chinese BBIBP- CorV vaccines are already 
rolled out in some high- income countries, 
and other vaccines may follow. While in 
low- income and middle- income countries 
(LMICs) access is lagging, there are several 
vaccines with significant potential for fighting 
the pandemic in those LMICs that need 
them. For instance, Coronavac, developed by 
China’s Sinovac Biotech, has been approved 
in China and is undergoing phase III trials 
in several LMICs, including Brazil, Indo-
nesia, Bangladesh and the Philippines. By 
early December, Brazil and Indonesia had 
received over a million doses of the vaccine. 
The Sputnik V vaccine has been approved 
in Russia. The Oxford/AstraZeneca vaccine 
is being rolled out in India. The advantage 
of these last three vaccines is that they can 
be transported, stored and delivered using 
the standard 2°C–8°C cold chain infrastruc-
ture (the Pfizer vaccine needs to be kept at 
−70°C and Moderna at −20°C). Based on 
currently available information, the Oxford/
AstraZeneca vaccine is also likely to cost less 
than competitor vaccines, partly because of 
its different design, but also because Astra-
Zeneca has committed to selling it at cost 
during the pandemic and in perpetuity to 
LMICs.
The speed of the response to COVID-19 has 
been made possible by massive public invest-
ments aimed at supporting innovation. Since 
February 2020, the public sector has invested 
€93 billion in COVID-19 vaccines and thera-
peutics.1 Roughly a third of this investment 
has come from the USA, 24% from the Euro-
pean Union and 13% from Japan and South 
Korea. Some governments, especially Britain 
and the European Union, have also made 
significant contributions to COVAX, a global 
initiative to support delivery of affordable 
COVID-19 vaccines to LMICs that aims to 
provide two billion doses by the end of 2021. 
COVAX is led by the WHO and coordinated 
by the WHO, Gavi, the Vaccine Alliance, and 
the Coalition for Epidemic Preparedness 
Innovations with initial funding from the Bill 
and Melinda Gates Foundation. Much work 
remains to purchase adequate amounts of 
COVID-19 vaccines and to distribute them 
equitably in LMICs,2 especially as richer coun-
tries buy up initial vaccine supplies, potentially 
undermining the ability of COVAX to deliver, 
and many middle- income countries seek to 
purchase their own supplies, with plans to 
start vaccinating early 2021.3 Nevertheless, 
the scale and pace of the global mobilisation 
of resources thus far—including financial 
investment, political will and advocacy—are 
remarkable and unprecedented.
Witnessing this remarkable achievement 
compels us to reimagine what is possible for 
other global health challenges. What if similar 
Summary box
 ► The resources that have been mobilised to ac-
celerate the development and distribution of the 
COVID-19 vaccine are unprecedented.
 ► We ask what could be achieved if similar resources 
were dedicated to improving access to medicines 
and other health technologies for conditions that af-
fect many more people.
 ► In 2017, an estimated two billion people did not have 
access to essential medicines, including for diseases 
with well- established treatment options like cardio-
vascular disease and diabetes.
 ► The COVID-19 vaccine experience has shown us the 
scale and pace of resource mobilisation and inno-
vation that we are capable of – this must now be 
applied to ensuring equitable access not only to the 
COVID-19 vaccine but to all essential medicines and 
health technologies.
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resources were mobilised for other essential medicines 
and vaccines, including for conditions that affect many 
more people than COVID-19? Or what if these resources 
were invested in strengthening health systems and access 
to health technologies overall in LMICs, integrating 
COVID-19 vaccination (where vaccination for COVID-19 
is warranted) with programmes to vaccinate against other 
diseases, or to detect, diagnose and treat other common 
conditions?4 How many more lives could be saved or 
dramatically improved? In 2017, an estimated two billion 
people did not have access to essential medicines.5 These 
included medicines for neglected tropical diseases, where 
investment in research and development (R&D) for 
effective treatments is well below what is needed, as well 
as for diseases with well- established treatment options 
such as HIV/AIDS, tuberculosis and malaria, which are 
often simply unavailable or unaffordable to those who 
need them. And while coverage of essential vaccina-
tions in low- income countries has increased significantly 
in the last decade, coverage of newer vaccines like the 
human papillomavirus vaccine, which protects against 
the leading cause of cervical cancer, remains very low 
(7%).6 COVID-19 has likely further exacerbated these 
problems—already scarce resources have been diverted 
away from these health issues and to COVID-19, medi-
cine supply chains have been disrupted, and millions of 
patients and their families are at risk of losing their liveli-
hoods, pushing them into poverty.
The problem of access to medicines is also increasingly 
relevant for non- communicable diseases (NCDs), which 
now make up 7 of the 10 leading causes of death world-
wide.7 Among NCDs, cardiovascular disease (CVD) is the 
leading cause of death, killing almost 18 million people 
each year. Contrary to the perception of CVD as a ‘disease 
of the rich’, four out of five CVD deaths occur in LMICs 
and half of these are among people under 70 years of 
age, many in the prime of their productive years.8 Despite 
the massive health and economic burden caused by CVD, 
essential medicines long used for primary and secondary 
prevention, including blood pressure- lowering drugs 
and statins, are unavailable or unaffordable to a large 
proportion of people in some LMICs.9 The same is true 
for fixed- dose combination therapies for hypertension, 
which combine two to three blood pressure- lowering 
medications into one pill, improve treatment adherence, 
lower healthcare costs and reduce major CVD events, 
even though they are listed on the WHO Essential Medi-
cines List.10 Non- vitamin K antagonist oral anticoagulants 
(NOACs) are a proven safe and effective treatment for 
non- valvular atrial fibrillation, reducing stroke, intracra-
nial haemorrhage and mortality. Unlike vitamin K antag-
onist oral anticoagulants that are more frequently used 
in LMICs, NOACs pose a lower risk of bleeding, are less 
likely to interact with other drugs or foodstuffs and do 
not require regular monitoring, all of which make them 
well suited to resource- poor health systems in LMICs.11 
In 2019 NOACs were added to the WHO Essential Medi-
cines List, but they remain unavailable or unaffordable 
in those countries that could benefit from them the 
most.11 12 Insulin, an essential treatment for diabetes, was 
discovered nearly 100 years ago and its patent sold for only 
$1 to the University of Toronto. Today, one out of every 
two people in LMICs who need insulin cannot access it 
(although lack of access is not limited to LMICs).13
Of course, access to essential medicines depends on 
supportive national policies. Countries can facilitate 
access by including these medicines in national essential 
medicines lists, in clinical treatment guidelines, among 
those drugs reimbursed or subsidised by national health 
insurance, and by ensuring that distribution systems 
deliver consistent supplies to drug dispensaries, pharma-
cies and health facilities. But actions taken at the interna-
tional level to support R&D, manufacturing, procurement 
and supply are also crucial. Voluntary licensing, through 
mechanisms such as the Medicines Patent Pool (MPP), 
can allow generic companies in LMICs to produce and 
sell essential medicines still under patent for a fraction of 
the cost of branded versions. For example, the MPP has 
estimated that in Sub- Saharan Africa and in low- income 
and lower- middle income countries in other regions, 
licensing agreements for NOACs still under patent 
protection could avert 10 000–31 000 cases of stroke or 
systemic embolism, or 94 000–281 000 venous throm-
boembolism events over a period of 4 years.12 When 
voluntary licensing cannot be obtained, countries must 
be encouraged to use existing legal flexibilities in inter-
national intellectual property laws to overcome patent 
barriers that stand in the way of public health.14 Where 
drugs are long off patent, including the components 
of fixed- dose combination therapies for hypertension, 
other strategies are required. We have seen that inclusion 
of these medicines in the WHO Essential Medicines List 
alone is not sufficient to support access, so we need more 
research to understand systemic barriers to access to 
medicines.10 This research should be done in collabora-
tion with communities, using methods that enable co- cre-
ation of interventions at the local health system level.15 
Importantly, it is necessary to place these measures within 
a comprehensive global strategy, with advocacy at all 
levels and incorporation of these drugs in international 
guidelines. This will require much greater commitment 
by global actors to work together—including multilat-
eral and national health organisations, governments 
and advocacy groups, pharmaceutical companies and 
researchers—to identify and address barriers to afford-
able access to essential medicines.
The priority given to COVID-19 vaccines and other 
COVID-19 health technologies is warranted. Normal life 
has been upended by the pandemic. Lives have been lost 
and livelihoods destroyed, children have missed school, 
domestic violence has increased, and the mental health of 
many has been negatively affected. People have suffered 
critical illness and died alone, separated from their loved 
ones. Yet this scale of loss and economic devastation was 
familiar to many people in different parts of the world 
long before COVID-19, where households have been 
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impoverished by the high cost of healthcare including 
essential medicines, and patients have had to forgo treat-
ment altogether and risk death due to unavailability or 
prohibitive prices.16 And the pandemic has only made 
the situation worse. Efforts by the global health commu-
nity to forewarn inequity in distribution of the COVID-19 
vaccine to LMICs and commitments to prevent this ineq-
uity are laudable, but for many in these countries there 
is nothing new about poor access to essential medicines. 
For NCDs specifically, the United Nations committed in 
2014 and again in 2018 to ensure access for all to afford-
able essential medicines for NCDs. This commitment was 
reiterated in the WHO target to achieve 80% availability 
of affordable, safe and efficacious NCD medications and 
in the Sustainable Development Goals. We are far from 
realising these intentions, but what the COVID-19 vaccine 
experience has shown is that it is possible for the interna-
tional community to try harder when it decides to do so.
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